H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

Kratom has been used for hundreds of years in Southeast Asia for issues like fatigue. But it's banned in at least 6 states.

Kratom is known for its stimulant and opioid-like effects and is derived from the leaves of a tree in the coffee family, the Southeast Asian tree Mitragyna speciosa. This differs from another natural ...

The South Dakota House of Representatives set aside political differences on Wednesday and found a topic that all of the lawmakers could agree on — passing ...

For more audio journalism and storytelling, download New York Times Audio, a new iOS app available for news subscribers. transcript This transcript was created using speech recognition software ...